文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

CYP2C19基因型与西酞普兰治疗结局的真实世界关联

CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real-World Setting.
PubMed 文献 · Clin Pharmacol Ther · 2026-04-14

基于英国生物银行11,079例西酞普兰处方患者,评估CYP2C19基因型与治疗结局的关联。CYP2C19超快代谢者治疗失败风险升高(OR 2.03,P=0.002),慢代谢者和超快代谢者治疗抵抗风险均呈升高趋势。CYP2C19代谢状态与维持剂量和加量时间呈单调趋势,罕见变异分析提示BMP2K为SSRI反应新候选基因。

要点

  • CYP2C19超快代谢者使用西酞普兰治疗失败风险显著升高(OR 2.03,P=0.002)。
  • CYP2C19代谢状态与西酞普兰维持剂量及加量时间呈显著单调趋势,提示呈U型关联。
  • BMP2K罕见变异与西酞普兰治疗失败相关(P=5.49×10-6),并在艾司西酞普兰使用者中复制(P=0.042)。

核心结论

  • CYP2C19基因型与真实世界西酞普兰治疗结局显著相关,呈U型关联:超快代谢者治疗失败风险升高(OR 2.03,P=0.002)。
  • 慢代谢者(OR 1.85,P=0.06)与超快代谢者(OR 1.74,P=0.05)治疗抵抗可能性均升高。
  • BMP2K被确定为可能影响SSRI反应个体差异的新候选基因。

研究设计与样本

  • 基于英国生物银行11,079例西酞普兰处方患者的真实世界数据,评估CYP2C19基因型与处方数据的关联。
  • 患者治疗未由药物基因组学指导,避免开放标签知晓与基因检测的期望偏倚。
  • 罕见变异分析在220例艾司西酞普兰使用者中进行了复制验证。

主要发现

  • CYP2C19超快代谢者治疗失败风险升高(OR 2.03,P=0.002)。
  • CYP2C19慢代谢者(OR 1.85,P=0.06)和超快代谢者(OR 1.74,P=0.05)治疗抵抗可能性升高。
  • CYP2C19代谢状态与维持剂量呈单调趋势(慢代谢者19.7 mg/d至超快代谢者24.4 mg/d;Jonckheere-Terpstra P=0.017)。
  • CYP2C19代谢状态与加量时间呈单调趋势(慢代谢者2.5年至超快代谢者1.7年;P=0.006)。
  • BMP2K变异与西酞普兰治疗失败相关(P=5.49×10-6),在220例艾司西酞普兰使用者中复制(P=0.042),且变异负荷越高维持剂量越低。

关键数值与推荐

  • CYP2C19超快代谢者治疗失败OR 2.03(P=0.002)。
  • CYP2C19慢代谢者治疗抵抗OR 1.85(P=0.06),超快代谢者OR 1.74(P=0.05)。
  • 维持剂量由慢代谢者19.7 mg/d至超快代谢者24.4 mg/d(Jonckheere-Terpstra P=0.017)。
  • 加量时间由慢代谢者2.5年至超快代谢者1.7年(P=0.006)。
  • BMP2K变异与西酞普兰治疗失败相关P=5.49×10-6,艾司西酞普兰复制P=0.042。

临床怎么用

  • 对西酞普兰治疗失败或抵抗患者,可考虑CYP2C19基因型检测以辅助解释疗效差异。
  • CYP2C19超快代谢者可能需关注治疗失败风险,慢代谢者可能需关注治疗抵抗与剂量调整。
  • BMP2K作为新候选基因,尚需进一步验证后再用于临床决策。

局限性

  • 研究基于处方数据推断治疗结局,可能受处方行为与依从性等混杂因素影响。
  • CYP2C19慢代谢者治疗抵抗的P=0.06、超快代谢者P=0.05,部分关联未达常规显著性阈值。
  • BMP2K关联在220例艾司西酞普兰使用者中复制,样本量有限,需更大规模验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CYP2C19 metabolizes various selective serotonin reuptake inhibitors (SSRIs) and genetic CYP2C19 variants are associated with SSRI tolerability and response. Yet, whether CYP2C19 variability also impacts citalopram response remained unclear. We here evaluated associations between CYP2C19 genotypes and citalopram prescription data of 11,079 patients from the UK Biobank. Importantly, CYP2C19 ultrarapid metabolizers (UMs) were more likely to experience therapeutic failure (OR 2.03, P = 0.002) and both CYP2C19 poor metabolizers (PMs) and UMs exhibited an increased likelihood of treatment resistance (PMs, OR 1.85, P = 0.06; UMs, OR 1.74, P = 0.05). Furthermore, inferred CYP2C19 metabolizer status showed significant monotonic trends with citalopram maintenance dose (from 19.7 mg/d in PMs to 24.4 mg/d in UMs; Jonckheere-Terpstra P = 0.017) and time to dose escalation (2.5 years in PMs to 1.7 years in UMs; P = 0.006). Besides CYP2C19, rare variant analyses identified BMP2K as a novel candidate locus for SSRI response. BMP2K variants were significantly associated with therapeutic failure in citalopram patients (P = 5.49 × 10-6) and this association was replicated in 220 escitalopram users (P = 0.042). Furthermore, higher BMP2K variant burden significantly correlated with lower maintenance dose. These findings provide the first report of a U-shaped association between CYP2C19 metabolizer status and citalopram therapeutic outcomes and pinpoint BMP2K as a novel candidate gene with potential contribution to interindividual differences in citalopram response. Collectively, these results demonstrate that CYP2C19 genotype is significantly associated with citalopram outcomes in a real-world setting in which patient treatment was not guided by pharmacogenetics, thus avoiding open-label awareness, eliminating expectation bias of genetic testing and highlighting the value of large-scale biobank data for advancing precision psychiatry.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Park Y, Zhou Y, Lauschke VM, et al. CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real-World Setting. Clin Pharmacol Ther. 2026. PMID: 41979220. doi:10.1002/cpt.70285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。